
BeOne Highlights Phase 3 CLL Data in Patients Aged 80+ at EHA 2026, Supporting BRUKINSA Benefits
BeOne Medicines Highlights Long-Term BRUKINSA Benefits in Older CLL Patients at EHA 2026 BeOne Medicines Ltd., a global oncology company dedicated to advancing innovative cancer therapies, has announced the presentation…












